Toll Free: 1-888-928-9744

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 1186 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016', provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
- The report assesses Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 10 Glioblastoma Multiforme (GBM) Overview 11 Therapeutics Development 12 Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 14 Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 30 Glioblastoma Multiforme (GBM) - Pipeline Products Glance 33 Glioblastoma Multiforme (GBM) - Products under Development by Companies 37 Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 57 Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 61 Glioblastoma Multiforme (GBM) - Therapeutics Assessment 235 Drug Profiles 270 Glioblastoma Multiforme (GBM) - Dormant Projects 1108 Glioblastoma Multiforme (GBM) - Discontinued Products 1122 Glioblastoma Multiforme (GBM) - Product Development Milestones 1125 Appendix 1148
List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2016 49 Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016 50 Number of Products under Development by Companies, H1 2016 52 Number of Products under Development by Companies, H1 2016 (Contd..1) 53 Number of Products under Development by Companies, H1 2016 (Contd..2) 54 Number of Products under Development by Companies, H1 2016 (Contd..3) 55 Number of Products under Development by Companies, H1 2016 (Contd..4) 56 Number of Products under Development by Companies, H1 2016 (Contd..5) 57 Number of Products under Development by Companies, H1 2016 (Contd..6) 58 Number of Products under Development by Companies, H1 2016 (Contd..7) 59 Number of Products under Development by Companies, H1 2016 (Contd..8) 60 Number of Products under Development by Companies, H1 2016 (Contd..9) 61 Number of Products under Development by Companies, H1 2016 (Contd..10) 62 Number of Products under Development by Companies, H1 2016 (Contd..11) 63 Number of Products under Development by Companies, H1 2016 (Contd..12) 64 Number of Products under Development by Companies, H1 2016 (Contd..13) 65 Number of Products under Development by Companies, H1 2016 (Contd..14) 66 Number of Products under Investigation by Universities/Institutes, H1 2016 67 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 68 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 69 Comparative Analysis by Late Stage Development, H1 2016 70 Comparative Analysis by Clinical Stage Development, H1 2016 71 Comparative Analysis by Early Stage Development, H1 2016 72 Comparative Analysis by Unknown Stage Development, H1 2016 73 Products under Development by Companies, H1 2016 74 Products under Development by Companies, H1 2016 (Contd..1) 75 Products under Development by Companies, H1 2016 (Contd..2) 76 Products under Development by Companies, H1 2016 (Contd..3) 77 Products under Development by Companies, H1 2016 (Contd..4) 78 Products under Development by Companies, H1 2016 (Contd..5) 79 Products under Development by Companies, H1 2016 (Contd..6) 80 Products under Development by Companies, H1 2016 (Contd..7) 81 Products under Development by Companies, H1 2016 (Contd..8) 82 Products under Development by Companies, H1 2016 (Contd..9) 83 Products under Development by Companies, H1 2016 (Contd..10) 84 Products under Development by Companies, H1 2016 (Contd..11) 85 Products under Development by Companies, H1 2016 (Contd..12) 86 Products under Development by Companies, H1 2016 (Contd..13) 87 Products under Development by Companies, H1 2016 (Contd..14) 88 Products under Development by Companies, H1 2016 (Contd..15) 89 Products under Development by Companies, H1 2016 (Contd..16) 90 Products under Development by Companies, H1 2016 (Contd..17) 91 Products under Development by Companies, H1 2016 (Contd..18) 92 Products under Development by Companies, H1 2016 (Contd..19) 93 Products under Investigation by Universities/Institutes, H1 2016 94 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 95 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 96 Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 97 Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H1 2016 98 Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H1 2016 99 Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H1 2016 100 Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications S.A., H1 2016 101 Glioblastoma Multiforme (GBM) - Pipeline by Advanced Cancer Therapeutics, H1 2016 102 Glioblastoma Multiforme (GBM) - Pipeline by Advantagene, Inc., H1 2016 103 Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H1 2016 104 Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH , H1 2016 105 Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H1 2016 106 Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H1 2016 107 Glioblastoma Multiforme (GBM) - Pipeline by Ambrx, Inc., H1 2016 108 Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H1 2016 109 Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 110 Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H1 2016 111 Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H1 2016 112 Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2016 113 Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 114 Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H1 2016 115 Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H1 2016 116 Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica AG, H1 2016 117 Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics, Inc., H1 2016 118 Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H1 2016 119 Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 120 Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc., H1 2016 121 Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H1 2016 122 Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H1 2016 123 Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H1 2016 124 Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H1 2016 125 Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 126 Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H1 2016 127 Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2016 128 Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H1 2016 129 Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 130 Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 131 Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2016 132 Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H1 2016 133 Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H1 2016 134 Glioblastoma Multiforme (GBM) - Pipeline by Cellectis S.A., H1 2016 135 Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H1 2016 136 Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H1 2016 137 Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H1 2016 138 Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H1 2016 139 Glioblastoma Multiforme (GBM) - Pipeline by Clonz Biotech Private Limited, H1 2016 140 Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H1 2016 141 Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H1 2016 142 Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc., H1 2016 143 Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp., H1 2016 144 Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H1 2016 145 Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H1 2016 146 Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 147 Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC, Inc., H1 2016 148 Glioblastoma Multiforme (GBM) - Pipeline by Delenex Therapeutics AG, H1 2016 149 Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016 150 Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 151 Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 152 Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H1 2016 153 Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc., H1 2016 154 Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H1 2016 155 Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2016 156 Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2016 157 Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H1 2016 158 Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2016 159 Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H1 2016 160 Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 161 Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research, Inc., H1 2016 162 Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics, Inc., H1 2016 163 Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co., Ltd., H1 2016 164 Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H1 2016 165 Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc., H1 2016 166 Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 167 Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H1 2016 168 Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H1 2016 169 Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H1 2016 170 Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2016 171 Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H1 2016 172 Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016 173 Glioblastoma Multiforme (GBM) - Pipeline by Immunocore Limited, H1 2016 174 Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H1 2016 175 Glioblastoma Multiforme (GBM) - Pipeline by Immunovaccine, Inc., H1 2016 176 Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H1 2016 177 Glioblastoma Multiforme (GBM) - Pipeline by Incuron, LLC, H1 2016 178 Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 179 Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics, Inc., H1 2016 180 Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical, Inc., H1 2016 181 Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 182 Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H1 2016 183 Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H1 2016 184 Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc., H1 2016 185 Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 186 Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 187 Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma, Inc., H1 2016 188 Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co., Ltd., H1 2016 189 Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology, Inc., H1 2016 190 Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2016 191 Glioblastoma Multiforme (GBM) - Pipeline by LinXis B.V., H1 2016 192 Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 193 Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H1 2016 194 Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H1 2016 195 Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 196 Glioblastoma Multiforme (GBM) - Pipeline by MedImmune, LLC, H1 2016 197 Glioblastoma Multiforme (GBM) - Pipeline by Medivation, Inc., H1 2016 198 Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H1 2016 199 Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H1 2016 200 Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 201 Glioblastoma Multiforme (GBM) - Pipeline by MimiVax, LLC, H1 2016 202 Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc., H1 2016 203 Glioblastoma Multiforme (GBM) - Pipeline by Nemucore Medical Innovations, Inc., H1 2016 204 Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 205 Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc., H1 2016 206 Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem, Inc., H1 2016 207 Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corporation, H1 2016 208 Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 209 Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2016 210 Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H1 2016 211 Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H1 2016 212 Glioblastoma Multiforme (GBM) - Pipeline by Omniox, Inc., H1 2016 213 Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics, Inc., H1 2016 214 Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H1 2016 215 Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics, Inc., H1 2016 216 Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 217 Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 218 Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H1 2016 219 Glioblastoma Multiforme (GBM) - Pipeline by OXiGENE, Inc., H1 2016 220 Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H1 2016 221 Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics, Inc., H1 2016 222 Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016 223 Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H1 2016 224 Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine, Inc., H1 2016 225 Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech, Inc., H1 2016 226 Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co., Ltd., H1 2016 227 Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H1 2016 228 Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H1 2016 229 Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 230 Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma S.A., H1 2016 231 Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H1 2016 232 Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 233 Glioblastoma Multiforme (GBM) - Pipeline by Rgenix, Inc., H1 2016 234 Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt., H1 2016 235 Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H1 2016 236 Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H1 2016 237 Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H1 2016 238 Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc., H1 2016 239 Glioblastoma Multiforme (GBM) - Pipeline by Selvita S.A., H1 2016 240 Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau S.p.A., H1 2016 241 Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H1 2016 242 Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H1 2016 243 Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics, Inc., H1 2016 244 Glioblastoma Multiforme (GBM) - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016 245 Glioblastoma Multiforme (GBM) - Pipeline by StemGen S.p.A, H1 2016 246 Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H1 2016 247 Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 248 Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 249 Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences, Inc., H1 2016 250 Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H1 2016 251 Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H1 2016 252 Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co. KG, H1 2016 253 Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H1 2016 254 Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 255 Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H1 2016 256 Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 257 Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc., H1 2016 258 Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H1 2016 259 Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 260 Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H1 2016 261 Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc., H1 2016 262 Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2016 263 Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc., H1 2016 264 Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 265 Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H1 2016 266 Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H1 2016 267 Glioblastoma Multiforme (GBM) - Pipeline by Vyriad, H1 2016 268 Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals, Inc., H1 2016 269 Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 270 Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H1 2016 271 Assessment by Monotherapy Products, H1 2016 272 Assessment by Combination Products, H1 2016 273 Number of Products by Stage and Target, H1 2016 275 Number of Products by Stage and Mechanism of Action, H1 2016 289 Number of Products by Stage and Route of Administration, H1 2016 304 Number of Products by Stage and Molecule Type, H1 2016 306 Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2016 1145 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H1 2016 1146 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H1 2016 1147 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H1 2016 1148 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H1 2016 1149 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H1 2016 1150 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H1 2016 1151 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H1 2016 1152 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H1 2016 1153 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H1 2016 1154 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H1 2016 1155 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H1 2016 1156 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H1 2016 1157 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H1 2016 1158 Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2016 1159 Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H1 2016 1160 Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H1 2016 1161


List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2016 49 Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016 50 Number of Products under Development by Companies, H1 2016 51 Number of Products under Investigation by Universities/Institutes, H1 2016 67 Comparative Analysis by Late Stage Development, H1 2016 70 Comparative Analysis by Clinical Stage Development, H1 2016 71 Comparative Analysis by Early Stage Products, H1 2016 72 Assessment by Monotherapy Products, H1 2016 272 Assessment by Combination Products, H1 2016 273 Number of Products by Top 10 Targets, H1 2016 274 Number of Products by Stage and Top 10 Targets, H1 2016 274 Number of Products by Top 10 Mechanism of Actions, H1 2016 288 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 288 Number of Products by Top 10 Routes of Administration, H1 2016 303 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 303 Number of Products by Top 10 Molecule Types, H1 2016 305 Number of Products by Stage and Top 10 Molecule Types, H1 2016 305

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify